We used sulfonylureas as the active comparator as clinical guidelines used during the study period recommended DPP4 inhibitors and GLP-1-receptor agonists as well as sulfonylureas as second- or third-line glucose-lowering therapies [17], and no concern regarding an increased risk of cholangiocarcinoma with use of sulfonylureas has been raised
A m o n g themselves, they forge opinions and work out arguments and systems of proof.France: educating young television viewers 309 For young people of all ages, television and the various activities and interchanges to which it gives rise are important factors in the process of their socialization
The next generation PRP includes, PRF AND GFC
Weight Loss Efficacy and Comparative Effectiveness Superior Performance of Dual-Agonist Therapies The SURMOUNT-5 head-to-head trial represents a landmark study comparing the two leading GLP-1 medications directly ^2
At position 34 in the amino acid chain, native GLP-1 carries a lysine residue
Host-microbiota maladaptation in colorectal cancer